Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1474-760X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models ; volume:17 ; number:1 ; day:21 ; month:9 ; year:2016 ; pages:1-11 ; date:12.2016
Genome biology ; 17, Heft 1 (21.9.2016), 1-11, 12.2016
- Creator
-
Geeleher, Paul
- Contributor
-
Cox, Nancy J.
Huang, R. Stephanie
SpringerLink (Online service)
- DOI
-
10.1186/s13059-016-1050-9
- URN
-
urn:nbn:de:101:1-2018071920361988811073
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Geeleher, Paul
- Cox, Nancy J.
- Huang, R. Stephanie
- SpringerLink (Online service)
Other Objects (12)
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Opportunities for pharmacoproteomics in biomarker discovery
Avoiding false discovery in biomarker research
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease
Urine—an untapped goldmine for biomarker discovery?
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Opportunities for pharmacoproteomics in biomarker discovery
Avoiding false discovery in biomarker research
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease
Urine—an untapped goldmine for biomarker discovery?
Biomarker discovery
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Mass Spectrometry-Based Protein Biomarker Discovery and Measurement: Sensitivity is the Greatest Hurdle
Metagenomic biomarker discovery and explanation
Biomarker discovery an related topics, 2
Opportunities for pharmacoproteomics in biomarker discovery
Avoiding false discovery in biomarker research
Revisiting biomarker discovery by plasma proteomics
Advanced technologies, including new biomarker discovery
Preclinical discovery of ixabepilone, a highly active antineoplastic agent
GPS driving: a digital biomarker for preclinical Alzheimer disease